使用OSIMERTINIB治療非常見的EGFR NSCLC 突變

(1:27)

Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC

(3:19)

EGFR+ NSCLC中的FLAURA試驗

(1:22)

開發中的針對NSCLC的EGFR 抑制劑

(1:22)

Case 4: Metastatic EGFR+ NSCLC Progressing on Osimertinib

(6:41)

Treating Uncommon EGFR NSCLC Mutations with Osimertinib

(2:8)

當osimertinib治療EGFR突變的晚期肺癌出現MET基因擴增的抗藥性 該怎麼辦?

(11:50)

Lung Cancer can now be treated by a Tablet called Osimertinib, Tagrisso. Part 2 #cancer

(53)

EGFR突變肺癌的重大突破：泰格莎（Osimertinib）的發展歷程 Major Breakthrough in EGFR-Mutated NSCLC

(17:34)

Osimertinib + ipilimumab in EGFR-mutated NSCLC

(2:21)

Oleclumab plus osimertinib for advanced EGFRm NSCLC

(2:53)

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive NSCLC

(6:28)

Significance of the Phase III FLAURA Study in EGFR+ NSCLC

(2:27)

NSCLC中佐劑配製中的EGFR TKI

(1:45)

EGFR陽性晚期肺癌 第一線治療突破新進展-3. 2 針對L858R突變的治療概況

(9:2)

泰格莎第一線健保給付！EGFR突變肺癌的治療選擇更完整，但臨床決策挑戰依然存在 Osimertinib Now Covered for First-Line EGFR NSCLC

(8:42)

Lung Cancer can now be treated by a Tablet called Osimertinib, Tagrisso. Part 3 #cancer

(54)

EGFR陽性晚期肺癌 第一線治療突破新進展-4 第3代EGFR標靶第一線治療概況

(4:57)

Dr. Yang on Osimertinib as First-Line Therapy for EGFR-Positive NSCLC

(2:14)

Osimertinib in Advanced EGFR T790M-Mutant NSCLC

(3:2)